August 2016August 2016
New Product - Herceptin SC
Herceptin SC (trastuzumab (rch)) is a recombinant DNA derived humanized monoclonal antibody that selectively targets the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). Herseptin SC is indicated for the following. The treatment of HER2‑positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy. The treatment of HER2‑positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant Herceptin. The treatment of patients with metastatic breast cancer who have tumours that overexpress HER2: as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease; in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone‑receptor positive metastatic breast cancer. Herceptin is contraindicated in the treatment of early or locally advanced breast cancer. It is also contraindicated in patients with a left ventricular ejection fraction of less than 45% and those with symptomatic heart failure. It is also contraindicated in patients with known hypersensitivity to Chinese hamster ovary cell proteins. Herceptin SC is available as a ready to use solution (600 mg/5 mL) in a single use vial in packs of 1’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au